It is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions
Opioid dependence: Initially: 25 mg; increase to 50 mg daily if no withdrawal signs occur. Maintenance: 350 mg wkly given as 50 mg daily or divided in 3 doses for improved compliance. Adjunct in alcohol dependence: 50 mg daily.May be taken with or without food.May be taken with or without food.
It is contraindicated in: 1. Patients receiving opioid analgesics. 2. Patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). 3. Patients in acute opioid withdrawal . 4. Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. 5. Any individual with a it or any other components of this product. It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids
Abdominal pain, nausea, vomiting; anxiety, insomnia, lethargy, headache, musculoskeletal pain; anorexia, diarrhoea, constipation; increased thirst; chest pain; chills, dizziness; sexual dysfunction; rash, liver function abnormalities and reversible idiopathic thrombocytopenia
ither studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available
.png&w=384&q=75)